Full Press Release Details
Okay. And we're live. Alright, welcome everybody to Wall Street Reporter's
next super stock live stream where we bring you those stocks, which have that 10 x to 100 x upside potential companies going after massive
multi-billion dollar market opportunities. That already key inflection point right now. And with those multiple catalyst in place. And
of course, that brings us to ADTX, uh, Amro welcome back to the program.
Amro Albanna (00:27):
Thanks for having me, Jack. Great to see you again.
Amro absolutely looks, uh, ADTX. You know, like all of our stocks that
become 10 bagger, you know, and, and it's something that, you know, we talk about, you know, in the book, in the 10 bag or blueprint,
you know, all the case studies, all of em go through the same type of ride we're seeing right now with ADTX. It's a rollercoaster, right?
The stock doubled, you know, with like in the first day or up 85%, then it crashes back 50%. Now it's bouncing back. And, uh, it looks
like it's, it's ready to absolutely explode. And there's been some incredible news, which I want to get into in this interview. I want
to get your insights. Um, but the big news, I think, which the market missed yesterday is the, um, crypto treasury strategy. The Bitcoin
treasury strategy, which, uh, I think is a big deal.
The press release apparently came out on business wire. Yahoo didn't
pick it up because I think if Yahoo would've picked it up, the stock would've gone to maybe three or $5. cause we're seeing that, you
know, a lot. There's a, you know, any, any time companies announce this, you know, Bitcoin strategy, these things are exploding. But the
difference, I think in your case, actually, it actually makes sense for Aditxt in a lot of cases. I've, and I've been very, uh, critical
of a lot of companies doing this. In your case actually makes sense. I want to, we're going to get into this thing, uh, cause I think
it's a, it's a game changer for, for Aditxt, but, um, first we got a lot of new people watching. So, Amro, for, for those new to the,
to the story, can you tell us, you know, about the Aditxt business model and, you know, the, the kind of the, the, the growth drivers
Amro Albanna (02:05):
Yeah. Uh, so Jack, thanks again for having me. I mean, I, I truly enjoy
having these calls. cause look, as a public company, we wanna make sure that we engage with our stakeholders. We want em to understand
what Aditxt is all about. And to summarize our business model, we are publicly owned innovation accelerator. If you understand that about
Aditxt, you pretty much can understand kind of the strategies we're taking to achieve this vision, publicly owned innovation accelerator.
Or as, as, as I call you a unicorn farm. I, I look this as a unicorn
farm. You're growing these little unicorns, which are, you know, then you, you, you monetize them. But I'm, I'm sorry to you.
Amro Albanna (02:47):
No, no, no. That's, that's, no, no, that's perfectly fine. And look,
when we're talking about innovation accelerator, we identify these big opportunities, these big potential opportunities. We bring em
in house, we build them for growth, and we look to monetize em at the end of the road. That's our business model. And we are business
builders. We're not transactional. We, again, we identify these opportunities to bring em in house and build the business hands-on and,
and begin to capitalize and monetize these opportunities in one form or another, which we can get into. But that's who we are as a business.
If you, if you want to talk about crypto, look, I mean, there is no secret that a lot of public companies have been, you know, uh, picking
up crypto, uh, you know, for one reason or another. I mean, some companies became a crypto company, you know, by reverse merging into
other crypto companies.
Uh, some basically became crypto holding companies. That's not who
we are. When you look at publicly owned company and combined with innovation acceleration, the, the public ownership side of it is we
look at crypto and digital currency in general as another, another way to broaden our shareholder base, right? Um, it is here, it is here
to stay, I believe, just like many of the transforming technologies that we've seen in the past. And it is a way for us to broaden our
shareholder base and with a goal and hope that it will begin to align our enterprise value with our potential value, right? Which is a
macro issue in the market right now, with everything we're doing, we're still at four or $5 million market cap. We're hoping that it will
begin, at least it becomes a tool to align our enterprise value with our potential value. So that's how we view crypto.
Amro Albanna (04:39):
And, and I forgot to turn off my phone, so I can turn it off.
Okay. And, and again, one talk about enterprise value, right? So look,
anytime we bring a company onto our, you know, our next super stock platform, we have a strict list of criteria, right? We're looking
for companies, which they have to have that 10 x upside potential. Uh, and in the case of Aditxt, you know, I'm looking at this and I
see this, again, you're trading at a 5 million market cap, but the assets that you have, which we're gonna get into in a, in, in a, in
a second, you know, potentially they're worth a hundred million plus in terms of when, when you can fully monetize them, which means that
Delta is about 20 x. So this stock potentially could be worth, you know, $25 a share. Now, we have to discount, obviously, you know, you
know, we, we got discount, you know, for everything. But, you know, we see a path to 10 x from here.
We'll talk about, you know, kind of your, your growth initiatives.
We'll talk about, again, was it Pearsanta? You have, uh, Adimune, you got, uh, Evofem the acquisition you're gonna be making. I mean,
just the, what's, you know, and we, we can just mention this. So Evofem, the company that you're, uh, in the process of acquiring women's
health, they're doing 20 million in revenues. Um, and again, they've had some issues because of previous toxic financing. It's, it, it's
kind of a, an oddball situation. But I think once you have it under the umbrella of Aditxt and, and we kind of clean up the balance sheet
and all that, this thing should be worth, again, within the Aditxt, uh, uh, umbrella, you know, five x revenues, which I think is conservative,
which means a hundred million plus valuation. Uh, and that's just one of your baby unicorns. This is like, uh, again, so you got, you
got the, uh, Evofem, uh, baby unicorn number one. You got Pearsanta, which, and we should talk about this now, this Pearsanta, I think
you mentioned earlier, this was, you were talking to some bankers about doing an IPO. This is the, um, cancer detection company, right?
Amro Albanna (06:34):
Yeah. Yeah. So, uh, you know, so, you know, I mean, especially for
those who haven't really heard me before, we obviously do not get in the business of, uh, you know, forecasting a share price, right?
It is, it is always gonna be a function of market. But I would truly like to discuss the opportunity and the potential of each company,
Jack. And then, you know, shareholders, investors can make up their mind based on the available information, based on the opportunity,
right? Of course. Look, um, you know, speaking of unicorns, I mean, if you wanna call a value for each one, right? So let's begin with
Pearsanta. And it is important to share with your audience, uh, and our shareholders. What is the value of Pearsanta? I mean, look, we
completed the acquisition, asset acquisition of flow cytometry, uh, Mitomic platform, uh, Adductomics platform. And ultimately look at
Pearsanta as a value.
What is the value for Pearsanta in terms of what is the value for humanity?
Let's begin with cancer. As far as early detection of cancer, you know, we don't need slides. We don't need market data for us to realize
what a deadly disease. It's what a major issue for humanity when it comes to cancer. And I think we would agree that early detection and
timely detection of cancer is, is beyond valuable, right? To say valuable as an understatement. So what we're doing with Pearsanta is
we're using mitochondrial DNA to early detect cancer, which as we all agree, early detection of cancer is key. So that's number one. And
we're currently going through the validation process in our CLIA CAP facility, which is Pearsanta's facility out of Richmond, Virginia,
with a goal to go commercial potentially by end of this year, but likely by Q1 of 2026. This, you know, in a matter of six months. So
assuming we finished the validation and we begin commercially offering cancer detection, starting with prostate cancer and endometriosis,
which is obviously not cancer, but that is for women's health. These are the two tests that we would go out in Q1 of 2026, just in few
Is happening now. This is, and this is not, this is, the path to commercialization
is like within six months, basically.
Amro Albanna (08:48):
So 2026, and you'll see me say, you, you'll, you'll hear me say this
over and over again. Look, we've been building a, as a model for acquiring, building, capitalizing these opportunities, right? 2026. We,
we we're focused on proving the business model by achieving these capitalization events and monetization events. And I'll have to say,
Jack, you know, as a public company, we can't guarantee it. You gotta lead, you gotta read all the disclaimers. It is, it's what it is.
But we are moving quickly towards commercialization of the first prostate ca of the first test, which is prostate cancer and endometriosis.
And that would be commercial validation of our business model,
Actually. Anyway, so actually you have a couple of, so you have a couple
of major catalysts in place. So, so your bi your business model, right? The business model is this innovation accelerator, or real, I
mean, it's almost like, again, for investors who may not be familiar with you, are basically a, you are almost like a venture capital
firm, except you're hands on in developing these businesses and you own them out, right? That's basically what it's, right. And we're
Amro Albanna (09:53):
These, right? So, so, right. So, so, so any investor buys a stock,
you got multiple shots on goal. So basically the anybody buying ADTX, they got multiple shots on goal. You have one, two, you have three
plus of these, uh, initiatives right now, you, you're probably gonna be adding more opportunities, but you have actually two that are
near term, which, uh, which is obviously Evofem closing that acquisition, which could happen in September. I think we're September timeline
more or less. Yeah. Okay. So we're a month away. We're a month away. And that, and that's a big deal because I think the reason the stock
is trading at a dollar, the reason you're trading at 5 million right now is nobody knows. I mean, people are, you know, they're confused.
They don't get it, whatever. But once they see it, because once they actually see this thing happening, oh, then it's real.